Review Article

Morpholino Antisense Oligomers: Design, Preparation, and Properties

JAMES SUMMERTON and DWIGHT WELLER

ABSTRACT

Antisense promised major advances in treating a broad range of intractable diseases, but in recent years progress has been stymied by technical problems, most notably inadequate specificity, ineffective delivery into the proper subcellular compartment, and unpredictable activity within cells. Herein is an overview of the design, preparation, and properties of Morpholino oligos, a novel antisense structural type that solves the sequence specificity problem and provides high and predictable activity in cells. Morpholino oligos also exhibit little or no nonantisense activity, afford good water solubility, are immune to nucleases, and are designed to have low production costs.

INTRODUCTION

0LIGONUCLEOTIDES, OLIGONUCLEOTIDE ANALOGS, and other sequence-specific binding polymers designed to block translation of selected messenger RNAs (the sense strand) are commonly called "antisense ohgos." Development of such oligos; for therapeutic applications, which constitutes the epitome of rational drug design, entails selecting a target genetic sequence unique and critical to the pathogen or pathogenic state one wishes to treat. One then assembles an oligomer of genetic bases (adenine, cytosine, guanine, and thymine or uracil) complementary to that selected sequence. When such an antisense oligo binds to its targeted disease-causing sequence, it can inactivate that target and thereby alleviate the disease.

Antisense oligos offer the prospect of safe and effective therapeutics for a broad range of intractable diseases. Nonetheless, developing therapeutics that function by a true antisense mechanism presents a number of forbidding challenges. The oligos should achieve adequate efficacy at a concentration attainable within the cells of the patient. They should inhibit their selected target sequences without concomitant attack on any other sequences in the patient's pool of approximately 200 million bases of unique-sequence RNA. They should be stable in extracellular compartments and within cells. They must be deliverable into the cellular compartment(s) containing their targeted sequences. They should be adequately soluble in aqueous solution. They should exhibit little or no toxicity at therapeutic concentrations. Finally, they should be affordable, reflecting the increasing

ANTIVIRALS Inc., Corvallis, OR 97333.

awareness that health care, even for life-threatening conditions, should not expend an excessive portion of society's resources.

First-generation antisense oligos comprised natural genetic material (Belikova et al., 1967; Zamecnik and Stephenson, 1978; Summerton, 1979) and often contained crosslinking agents for binding their targets irreversibly (Summerton and Bartlett, 1978a,b). As the design challenges became more fully appreciated, a number of nonnatural antisense structural types (Fig. 1) were developed in an effort to improve efficacy, stability, and delivery. Of particular note are the early non-ionic DNA analogs developed by Miller and Ts'o, including phosphotriester-linked DNA (Miller, 1989a) and methylphosphonate-linked DNA (Miller, 1989b). Other nucleic acid analogs of note include carbamate-linked DNA (Stirchak et al., 1987), phosphorothioate-linked DNA (Stein and Cohen, 1989). phosphoroamidate-linked DNA (Froehler et al., 1988), α-DNA (Rayner et al., 1989), and 2'-O-methyl RNA (Shibahara et al., 1989). Figure IB shows several novel antisense types that no longer resemble nucleic acids. These oligos contain acyclic backbone moieties, including nylon (Weller et al. 1991; Huang et al., 1991), the exceptionally high-affinity peptide nucleic acids (PNAs) (Egholm et al., 1992), and related types (Summerton and Weller, 1993a).

Although each of these newer structural types provides one or more significant advantages over the first-generation oligos, none yet appear to provide the full combination of properties needed in antisense therapeutics for clinical applications.

A. DNA, RNA & ANALOGS

DNA/RNA   Carbamate   α-DNA

| Type	R	X
DNA	H	O⁻
Phosphotriester	H	OCH₃
Methylphosphonate	H	CH₃
Phosphorothioate	H	S⁻
Phosphoroamidate	H	NHCH₃
RNA	OH	O⁻
2' O-methyl RNA	OCH₃	O⁻

B. ACYCLIC

Nylon

Peptide

Carbazate

FIG. 1. Representative antisense structural types.

Herein we describe the design considerations used in developing a novel Morpholino structural type (Fig. 2), which affords antisense oligos having very high efficacy and

B = adenine, cytosine, guanine, uracil

FIG. 2. Morpholino oligo structure.

specificity, immunity to nucleases, good aqueous solubility, and low production costs

DESIGN

Backbone structure

A dominant consideration in the design of most antisense oligos has been to devise a structure that provides resistance to nucleases while still resembling natural nucleic acids as closely as possible. This conservative approach has spawned a number of DNA analogs (Fig. 1A) that may be unduly expensive for routine applications requiring systernic delivery. The high cost of DNA and its analogs is due in part to the low abundance of DNA in production-scale source material and the difficulty in cleaving DNA to the deoxyribonucleosides required for preparing DNA analogs. An additional factor in their high cost is the complexity and expense of coupling to hydroxyls, required in forming the phosphoester intersubunit linkages of most DNA analogs.

Rather than trying to solve inherent cost problems after a structural type has been developed, a better approach is to incorporate fundamental cost advantages in the initial structural design stage. Following this strategy, we reasoned that more affordable antisense oligos might be possible if inexpensive ribonucleosides could be exploited as starting material. The order-of-magnitude cost advantage of ribonucleosides relative to deoxyribonucleosides (Summerton, 1992) derives from the sixfold greater abundance of RNA relative to DNA in productionscale source material (e.g., yeast cake) and the ease of cleaving

RNA to its component ribonucleosides. It is noteworthy that ribonucleosides are now directly available from special excreting strains of yeast, further reducing their cost. However, the use of ribonucleosides for preparation of RNA and RNA analogs presents two serious problems. First, during oligo assembly, one must selectively couple either the 2' or the 3' hydroxyl. This is typically achieved in a relatively expensive manner by selectively masking the 2' hydroxyl with a cleavable or noncleavable moiety. The second problem is that coupling to the 3' hydroxyl of the riboside is even more difficult and expensive than the corresponding coupling of deoxyribonucleosides.

We envisioned that these problems could be circumvented by converting the riboside moiety to a morpholine moiety (Stirchak et al., 1989; Summerton, 1990) (Fig. 3). Although oligomers assembled from such Morpholino subunits differ substantially from DNA, RNA, and analogs thereof, our initial modeling studies carried out in 1985 suggested that such novel Morpholino-based oligomers might constitute useful and highly cost-effective antisense agents. The simple and inexpensive ribose to morpholine conversion shown in Figure 3 replaces two poor nucleophiles (the 2' and 3' hydroxyls) with a single good nucleophile (the morpholine nitrogen) and allows oligo assembly via simple and efficient coupling to the morpholine nitrogen without the expensive catalysts and postcoupling oxidation steps required in the production of most DNA-like antisense ohgos. It is noteworthy that in spite of the relatively low nucleophilicity of the morpholine nitrogen (pK$_a$ = 5.75), we still typically achieve coupling efficiencies of 99.7% without using catalysts.

Intersubunit linkage

We have assessed a substantial number of intersubunit linkage types, including the carbonyl, sulfonyl, and phosphoryl linkages (Fig. 4) (Summerton and Weller, 1991, 1993a,b; Stirchak et al., 1989). Although Morpholino oligos containing a number of such linkages provide effective binding to targeted genetic sequences, consideration of cost and ease of synthesis, chemical stability, aqueous solubility, and affinity and homogeneity of binding to RNA led us to focus on the phosphorodiamidate shown in Figure 2 as our principle linkage type for oligos targeted against single-stranded RNA sequences. These non-ionic phosphorodiamidate-linked Morpholino oligos exhibit quite good binding to complementary nucleic acids, particularly RNA sequences. Table 1 compares the temperature of melting (T$_m$) values at physiologic salt concentration for identical-sequence 20-mer oligos of three different antisense structural types paired with their complementary RNA. As seen in Table 1, RNA binding affinity is lowest for the

phosphorothioate-linked DNA (S-DNA), appreciably higher for DNA, and highest for the Morpholino oligo.

PREPARATION

Oligo assembly

Although phosphorodiamidate-linked Morpholino oligos can be assembled by a variety of methods, one relatively simple method that has proved effective (Summerton and Weller, 1993b) entails protection and activation of the Morpholino subunit (Fig. 5A). The activated subunits can be stored at low temperatures for many months without significant breakdown. Whereas they are relatively resistant to hydrolysis, they react rapidly (T$_{1/2}$ of 1-2 minutes) with the morpholine nitrogen of growing chains on a 1% crosslinked polystyrene synthesis support loaded at 500 μM/g of resin, with coupling efficiencies typically about 99.7%. A preferred oligo assembly cycle (Summerton and Weller, 1993b) is shown in Figure 5B. It is noteworthy that in large-scale syntheses, excess activated subunit used in the coupling step can be recovered and reused, effecting a further substantial reduction in production costs.

Because of cheaper starting materials and simpler, more efficient oligo assembly, we estimate that in large-scale production, the cost of these Morpholino antisense oligos will be at least an order of magnitude lower than the cost of corresponding DNA analogs (Summerton, 1992).

PROPERTIES

Solubility

For an antisense oligo to have effective access to its target sequence within the cytoplasm of a cell, the oligo should show reasonable water solubility. Good water solubility may also prove essential for systemic delivery of antisense oligos. Conventional wisdom in the antisense field is that non-ionic antisense oligos invariably show poor water solubility. In this regard, it is interesting that a Morpholino dimer containing a rigid carbamate linkage shows little or no base stacking (Kang et al., 1992), and in the absence of special solubilizing groups, Morpholino oligomers containing such carbamate linkages are quite insoluble in aqueous solutions (Stirchak et al., 1989). In contrast, phosphorodiamidate-linked Morpholino oligos of the type shown in Figure 2 show excellent base stacking (Kang et al., 1992) and are several orders of magnitude more soluble in aqueous solutions. To illustrate the exceptional aqueous solu-


B* = N4-benzoylcytosine, N6-benzoyladenine, N2-phenylacetylguanine, uracil

FIG. 3. Conversion of ribonucleoside to Morpholino subunit.

FIG. 4. Intersubunit linkage types for Morpholino oligos.

bility of Morpholino oligos of this type, we have dissolved 263 mg of a heteromeric 22-mer of the sequence 5'-GCUCGCA-GACUUGUUCCAUCAU in I ml of water (36 millimolal) at 20°C without reaching saturation.

We suggest that the poor water solubility of the carbamatelinked Morpholino oligos results at least in part from the difficulty of inserting the hydrophobic faces of the unstacked bases into an aqueous environment. In contrast, it seems likely that the excellent water solubility of the phosphorodiamidate-linked Morpholino oligos is a consequence of effective shielding of these hydrophobic faces from the polar solvent because of good stacking of the bases.

Biologic stability

To achieve reasonable efficacy, an antisense oligo should not be degraded rapidly either extracellularly or within cells. In this regard, it has been demonstrated that DNA and 2'-O-methyl RNA are rapidly degraded and phosphorothioate DNA is slowly degraded by nucleases in blood and within cells (Hoke et al., 1991; Morvan et al., 1993). Although resistance to nucleolytic degradation can be improved by adding special groups to the termini (Cazenave et al., 1987) or by incorporating a few nuclease-resistant intersubunit linkages near each end (Larrouy et al., 1992), we believe a better solution, on the basis of both function and cost, is to use a backbone structure that is inherently immune to a broad range of degradative enzymes present in the blood and within cells. A further advantage of using a backbone structure that is not degraded in the body is that it avoids concerns that modified nucleosides or nucleotides resulting from degradation of an antisense oligo might be toxic or might be incorporated into cellular genetic material and thereby lead to mutations or other undesired biologic effects.

In experiments detailed elsewhere (Hudziak et al., 1996), it is demonstrated that Morpholino phosphorodiamidate oligos of

TABLE 1. MELTING TENTERATURES OF RNA/OLIGO DUPLEXES

RNA/S-DNA	68.5°C
RNA/DNA	77.3°C
RNA/Morpholino	81.3°C

the type shown in Figure 2 are immune to a wide range of nucleases, including DNase I (an endonuclease that cleaves both single-stranded and double-stranded DNA), DNase H (cleaves between the 5' oxygen and the phosphorus of DNA linkages), RNase A (cleaves on the 3' side of pyrimidines), RNase TI (cleaves on the 3' side of guanines), nuclease PI (cleaves single-stranded RNA and DNA), phosphodiesterase (3' exonuclease for both RNA and DNA), Mung bean nuclease (cleaves single-stranded RNA and DNA), and benzonase (cleaves both single-stranded and double-stranded RNA and DNA, including linear, circular, and supercoiled). These Morpholino oligos have also been found to be immune to pronase E, proteinase K, and pig liver esterase, as well as degradative enzymes in serum and a liver homogenate.

Antisense efficacy

Because of the excellent RNA binding affinity of oligos of this phosphorodiamidate-linked Morpholino structural type, it seemed likely Morpholino oligos would be effective in blocking translation of their targeted mRNAs, and this has been found to be the case. In cell-free translation experiments using a sensitive luciferase reporter, we have demonstrated that a Morpholino oligo 25 subunits in length, in both the presence and absence of RNase H, inhibits its targeted mRNA somewhat better than the corresponding S-DNA oligo in the presence of added RNase H, with both showing good efficacy at concentrations of 10 nM and above. Representative translational inhibition results are shown in Figure 6 (Summerton et al., 1997). A similar comparison of Morpholino and S-DNA antisense oligos targeted against murine tumor necrosis factor-α (TNF-α) mRNA in a cell-free translation system also showed greater activity for the Morpholino oligos (Taylor et al., 1996).

Specificity

In the early days of antisense research, one of the most compelling arguments for antisense therapeutics was their promise of exquisite specificity for their targeted genetic sequences. However, as the most synthetically accessible antisense structural types (DNA and S-DNA) have come into broad use, it has become clear that these two structural types provide reasonable

FIG. 5. Protection, activation, and coupling of Morpholino subunits.


FIG. 6. Cell-free efficacy of Morpholino and S-DNA antisense oligos.

sequence specificity within only a very narrow concentration range (ANTIVIRALS Inc., 1993; Stein and Cheng, 1993).

We believe a key factor responsible for the low specificity of DNA and S-DNA oligos is their RNase H competency; that is, DNA and S-DNA form duplexes with complementary RNA that are readily cleaved by RNase H, an enzyme widely distributed in living organisms. The specificity problem arises because DNA/RNA and S-DNA/RNA duplexes as short as 5 base pairs in length are cleaved by RNase H (Crouch and Dirksen, 1982). Presuming about 6% of the genome is transcribed in higher animals, the patient's RNA pool will comprise about 200 million bases of unique-sequence RNA. With this level of sequence complexity, it is inevitable that antisense oligos will form many short transient duplexes with partially complementary nontarget sequences of inherent cellular RNAs. Cleavage of the RNA strand of such nontarget duplexes by endogenous RNase H (Larrouy et al., 1992; Cazenave et al., 1989) is expected to cause significant disruption of normal cellular translation. As this cleavage process releases the DNA or S-DNA in its original form, such oligos can continue the cycle of transiently pairing with additional nontarget cellular RNA sequences, cleavage of the RNA strand, and release of the antisense oligo. As a consequence, essentially every RNase H-competent oligo is expected to cleave hundreds to thousands of species of inherent cellular RNAs.

A second factor expected to contribute to superior specificity of Morpholino oligos relative to RNase H-competent types is that RNase H-independent oligos have far fewer potential targets in the inherent pool of cellular RNA. This is because most antisense structural types that do not support RNase H cleavage of their RNA targets have been found to be effective in blocking translation of their targeted mRNAs only when said oligos are complementary to sequences in the 5' leader region of that mRNA or when they are targeted against other special sites, such as splice junctions and transport signals [e.g., methylphos- phonate DNA (Walder and Walder, 1988), α-DNA (Rayner et al., 1989), 2'-O-methyl RNA (Shibahara et al., 1989), and Morphohno (Summerton et al., 1997)]. We estimate that such special targetable regions constitute on the order of 2%-5% of the sequeces in the cellular RNA pool. Presumably, this targeting limitation reflects the ability of ribosomes to displace essentially all antisense oligos during translocation down the coding region of mRNAs.

Because an antisense oligo that does not support RNase H cleavage cannot effectively block functioning of an RNA when said oligo is bound to sequences outside of special targetable regions, such an oligo only needs to distinguish its target sequence from those 2%-5% of the cellular RNA sequences comprising special targetable regions. In contrast, antisense oligos that form RNase H-cleavable duplexes with RNA can be effective when targeted essentially anywhere along an RNA transcript (Walder and Walder, 1988), presumably because RNase H cleavage at the target site of the antisense oligomer destroys the RNA, rendering moot the oligo displacement capability of translocating ribosomes. Accordingly, RNase H-competent oligos (DNA and S-DNA) face the much greater specificity challenge of distinguishing selected target sequences from essentially the entire pool of cellular RNA sequences. As a consequence, RNase H-independent oligos, such as Morpholinos, should enjoy a 20-fold to 50-fold advantage in sequence

specificity because of this more than order-of-magnitude reduction in the number of inherent nontarget cellular sequences of any given length that they can inhibit.

A third factor compromising the specificity of S-DNA oligos is their promiscuous binding to proteins (Krieg and Stein, 1995), including components of the cell's replication, transcription, and translation machinery.

Given these factors expected to limit the sequence specificity of RNase H-competent antisense structural types, particularly SDNA, we set out to compare sequence specificities of S-DNA and Morpholino antisense oligos. To this end, we carried out stringent specificity assays in a cell-free translation system using two oligos of each structural type (Summerton et al., 1997). In these experiments, one oligo was perfectly complementary to its target mRNA to provide a measure of the total inhibition afforded by that oligo type. The other oligo incorporated 4 mispairs to that same mRNA target sequence, with the longest run of perfect pairing comprising 10 contiguous base pairs, to provide an estimate of the low-specificity component of the inhibition. The difference between these two inhibition values at each concentration then provided a measure of the high-specificity component, which we denote as "sequence-specific inhibition."

Figure 7 (experimental as in Summerton et al., 1997) shows that the S-DNA oligo achieved reasonable efficacy at concentrations above about 10 nM, but the sequence-specific component of its inhibition dropped below 50% at concentrations of only 100 nM and higher. The corresponding Morpholino oligo achieved even better efficacy at 10 nM while maintaining good sequence specificity through 10,000 nM, the highest concentration tested. Thus, in this stringent test of specificity, the Morpholino oligo achieved highly effective and specific antisense activity over a concentration range more than two orders of magnitude greater than the concentration range wherein the corresponding S-DNA achieved reasonable efficacy and specificity.


FIG. 7.   Sequence specificity of Morpholino and S-DNA oligos.

Taylor et al., (1996) have reported that S-DNAs targeted against TNF-a mRNA showed very poor sequence specificity in a cell-free translation system, whereas the corresponding Morpholino oligos afforded good specificity over the full range tested.

Activity in cells

For effective biologic activity, an antisense oligo must gain entry into the cellular compartments where the target genetic sequence is synthesized, processed, and functions -- specifically, the cytosol/nuclear compartment. Our experiments with fluorescent-tagged Morpholino oligos suggested that these oligos enter mammalian cells by what appears to be endocytosis, but they do not appear to subsequently cross the endosomal or lysosomal membrane into the cytosol, based both on visualization of fluorescent-tagged oligos and a functional assay employing a transfected plasmid (Partridge et al., 1996). This result is in agreement with limitations on uptake of antisense oligos reported by others. Specifically, a number of studies have been reported that suggest that in the absence of experimental manipulations that compromise the cell membrane, both polyanionic oligos [e.g., S-DNA (Wagner et al., 1993; Tonkinson and Stein, 1994) and 2'-O-methyl RNA (Oberhauser and Wagner, 1992)] and non-ionic oligos [e.g., methylphosphonate DNA (Shoji et al., 1991) and PNAs (Bonham et al., 1995)] enter cells primarily or exclusively by endocytosis. Further, a number of studies on a variety of antisense structural types indicate that most or all of the antisense oligo that gains entry by endocytosis does not subsequently traverse

the endosomal or lysosomal membrane to enter in an intact form into the cytosol, where protein synthesis occurs (Oberhauser and Wagner, 1992; Shoji et al., 1991; Bonham et al., 1995).

However, we have found that antisense oligos can be easily delivered into cultured cells simply by passaging anchorage-dependent cells by the common procedure of scraping with a rubber policeman. This has been shown to achieve significant oligo entry into the cytosolic compartment if the oligo is present during the scraping (Partridge et al., 1996). Further, Morpholino oligos delivered into cells by such scrape loading show good activity and specificity therein, whereas corresponding S-DNA oligos (both antisense and control sequences) largely fail to inhibit their targets within scrape-loaded cells at concentrations up to 3 µM in the medium and instead are often stimulatory (Summerton et al., 1997). Figure 8 shows a comparison of the activities of representative Morpholino and S-DNA oligos in scrape-loaded cells (experimental as in Summerton et al., 1997).

Taylor et al. (1996) have also compared the activity of SDNA and Morpholino antisense oligos in cultured cells. In their studies, the S-DNAs were delivered into mouse macrophagelike cells (RAW 264.7) using lipofectin. Both oligo types were targeted against TNF-α mRNA, and treated cells were assessed for inhibition of lipopolysaccharide-induced TNF-a production. In agreement with our in-cell results, Taylor et al. report that both the antisense and control S-DNAs stimulated instead of inhibited TNF-α production, whereas the Morpholino antisense oligo, although poorly delivered into the cells, afforded significant and specific inhibition of TNF-α production.


FIG. 8. In-cell activities of Morpholino and S-DNA oligos.

In vivo *properties*

To date, our principal efforts have focused on optimizing the Morpholino structural type and on studying the properties of Morpholino oligos at the biophysical level, in cell-free translation systems, and in cultured cells. In light of the promising results from those studies, we and several collaborators are now shifting our focus to in vivo studies.

A very preliminary ranging study was carried out to assess acute toxicity. In this study, a representative 20-mer Morpholino oligo in phosphate-buffered saline was injected intravenously into mice at doses ranging from 88 mg/kg to 700 mg/kg. No acute toxicity was seen at any of these doses. However, over a period of 2 weeks, an effect on body weight gain and ruffled coat was observed at the highest dose. Using the results from this ranging study, an extensive toxicity study has been initiated and will be the subject of a future report.

In addition, a variety of efficacy studies in mice and rats are in progress to assess the possible use of Morpholino oligos for therapeutic applications. We are also investigating possible methods for improving the delivery of these oligos into the cytosol/nuclear compartment of cells in vivo.

DISCUSSION

Morpholino oligos meet key requirements for safe, effective, and affordable antisense therapeutics, including high efficacy at low nanomolar concentrations, high sequence specificity over a thousandfold concentration range, little or no nonantisense activity, total stability in blood and within cells, excellent water solubility, and low production costs relative to other antisense structural types. Our efforts are now focused on achieving effective delivery into the cytosol/nuclear compartment of cells by means suitable for therapeutic applications and on studying the activities of these oligos in animals.

ACKNOWLEDGMENTS

REFERENCES

ANTIVIRALS Inc. Technical Report 3 (1993). Comparative studies of efficacy and specificity of translation inhibition in reticulocyte lysates. Antisense Res. Dev. **3**, following p. 306.

BELIKOVA, A., ZARYTOVA, V., and GRINEVA, N. (1967). Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett. **7**,3557-3562.

BONHAM, M., BROWN, S., BOYD, A., BROWN, P., BRUCKEN-STEIN, D., HANVEY, J. THOMSON, S., PIPE, A., HASSMAN, F., BISI, J., FROEHLER, B., MATTEUCCI, M., WAGNER, R., NOBLE , S., and BABISS, L. (1995). An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res. **23**, 1197-1203.

CAZENAVE, C., LOREAU, N., THUONG, N., TOULME, J., and HE-LEN, C. (1987). Enzymatic amplification of translation inhibition of rabbit beta-globin mRNA mediated by antiniessenger oligodeoxynucleotides covalently linked to intercalating agents. Nucleic Acids Res. **15**,4717-4736.

CAZENAVE, C., STEIN, C., LOREAU, N., THUONG, N., NECKERS, L., SUBASINGHE, C., HELENE, C., COHEN, J., and TOULME, J. (1989). Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxymicleotides. Nucleic Acids Res. **17**,4255.

CROUCH, R., and DIRKSEN, M. (1982). Ribonuclease H. In: *Nucleases.* S. Linn and R. Roberts, eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY), pp. 211-241.

EGHOLM, M., BUCHARDT, 0., NIELSEN, P., and BURG, R. (1992). Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J. Am. Chem. Soc. **114**, 1895-1897.

FROEHLER, B., NG, P., and MATTEUCCI, M. (1988). Phosphoramidate analogues of DNA: Synthesis and thermal stability of heteroduplexes. Nucleic Acids Res. **16**, 4831-4839.

HOKE, G., DRAPER, K., FRIER, S., GONZALEZ, C., DRIVER, V., ZOUNES, M., and ECKER, D. (1991). Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. **19**, 5743-5748.

HUANG, S., NELSON, J., and WELLER, D. (1991). Acyclic nucleic acid analogs: Synthesis and oligomerization of gamma,4-diamino-2-oxo-1(2H)-pyrimidinepentanoic acid and sigma,4-diamino-2-oxo-1(2H)-pyrimidinehexanoic acid. J. Org. Chem. **56**, 6007--6018.

HUDZIAK, R., BAROFSKY, L., BAROFSKY, D., WELLER, D.L., HUANG, S-B., and WELLER, D.D. (1996). Resistance of Morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. **6**, 267-272.

KANG, H., CHOU, P., JOHNSON, C., WELLER, D., HUANG, S., and SUMMERTON, J. (1992). Stacking interactions of ApA analogues with modified backbones. Biopolymers **32**, 1351-1363.

KRIEG, A., and STEIN, C. (1995). Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein? Antisense Res. Dev. **5**, 241.

LARROUY, B., BLONSKI, C., BOIZIAU, C., STUER, M., MOREAU, S., SHIRE, D., and TOULME, J. (1992). RNase H-mediated inhibition of translation by antisense oligodeoxyribonucletides; Use of backbone modification to improve specificity. Gene **121**, 189-194.

MILLER, P. (1989a). Non-ionic antisense oligonucleotides: Oligonucleotide alkylphosphotriesters. In: *Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression.* J. Cohen, ed. (CRC Press, Inc., Boca Raton, FL), pp. 82-85.

MILLER, P. (1989b). Non-ionic antisense olgionucleotides: Oligonucleotides methylphosphonates. In: *Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression.* J. Cohen, ed. (CRC Press, Inc., Boca Raton, FL), pp. 85-92.

MORVAN, F., PORUMB, H., DEGOLS, G., LEFEBVRE, I., POMPON, A., SPROAT, B., RAYNER, B., MALVY, C., LEBLEU, B., and IMBACH, J. (1993). Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J. Med. Chem. **36**, 280-287.

OBERHAUSER, B., and WAGNER, E. (1992). Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol. Nucleic Acids Res. **20**,533-538.

PARTRIDGE, M., VINCENT, A., MATTHEWS, P., PUMA, J., STEIN, D., and SUMMERTON, J. (1996). A simple method for delivering Morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acids Drug Dev. **6**,169-175.

RAYNER, B., MALVY, C., PAOLEM, J., LEBLEU, B., PAOLETTI, C., and IMBACH, J. (1989). α-Oligodeoxynucleotide ana-

logues. In: Oligodeoxynucteotides: Antisense Inhibitors *of* Gene *Ex*pression. J. Cohen, ed. (CRC Press, Inc., Boca Raton, FL), pp. 119-136.

SHIBAHARA, S., MUKAI, S., MORISAWA, H., NAKASHEMA, H., KOBAYASHI, S., and YAMAMOTO, N. (1989). Inhibition of human immunodeficiency virus (IRV-1) replication by synthetic oligo RNA derivatives. Nucleic Acids Res. **17**, 239-252.

SHOJI, Y., AKHTAR, S., PERIASAMY, A., BERMAN, B., and JU LIANO, R. (1991). Mechanism of cellular uptake of modified oligodeoxymicleotides containing methylphosphonate linkages. Nu cleic Acids Res. **19**, 5543-5550.

STEIN, C., and CBENG, Y. (1993). Antisense oligonucleotides as ther apeutic agents-Is the bullet really magical? Science 261, 1004-4012.

STEIN, C., and COHEN, J. (1989). Phosphorothioate oligonucleotide analogs. In: Oligodeoxynucleotides: Antisense Inhibitors *of* Gene *Ex*pression. J. Cohen, ed. (CRC Press, Inc., Boca Raton, FL), pp. 97-117.

STIRCHAK, E., SUMMERTON, J., and WELLER, D. (1987). Un charged stereoregular nucleic acid analogues. 1. Synthesis of a cyto sine-containing oligomer with carbamate intermicleoside linkages. J. Org. Chem. **52**,4202-4206.

STTP.CHAK, E., SUMMERTON, J., and WELLER, D. (1989). Un charged stereoregular nucleic acid analogs: 2. Morpholino nucleo side oligorners with carbamate internucleoside linkages. Nucleic Acids Res. **17**, 6129-614 1.

SUMMERTON, J. (submitted in 1973, published in 1979). Intracellular inactivation of specific micleotide sequences: A general approach to the treatment of viral diseases and vitally mediated cancers. J. Theor. Biol. **78**,77-99.

SUMIVIERTON, J. (1990). Polynucleotide assay reagent and method. Canadian Patent 1,268,404.

SUMMERTON, J. (1992). Cost-effective antisense structures. In: Biotechnology International. (Century Press, London), pp. 73-77.

SUMMERTON, J., and BARTLETT, P. (1978a). Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5 dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA. J. Mol. Biol. **122**,145-162.

SUMMERTON, J., and BARTLETT, P. (1978b). Nucleic acid crosslinking agent and affinity inactivation of micleic acids therewith. US Patent 4,123,610.

SUMMERTON, J., STEIN, D., HUANG, S., MATTHEWS, P., WELLER, D., and PARTRIDGE, M. (1997). Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acids Drug Dev. **7**, 63-70.

SUMMERTON, J., and WELLER, D. (1991). Uncharged morpholino-based polymers having achiral intersubunit linkages. US Patent 5,034,506.

SUMMERTON, J., and WELLER, D. (1993a). Polynucleotide assay reagent and method. US Patent 5,217,866.

SUMMERTON, J., and WELLER, D. (1993b). Uncharged Morpholino-based polymers having phosphorus containing chiral intersubunit linkages. US Patent 5,185,444.

TAYLOR, M., PAULAUSKIS, J., WELLER, D., and KOBZIK, L. (1996). In vitro efficacy of Morpholino-modified antiscrise oligomers directed against tumor necrosis factor-a mRNA. J. Biol. Chem. 22,17445-17452.

TONKINSON, J., and STEIN, C. (1994). Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein-labeled phosphodiester and phosphorothioate oligodeoxymicleotides in HL60 cells. Nucleic Acids Res. 22,4268-4275.

WAGNER, R., MATTEUCCI, M., LEWIS, J. GUTIERREZ, A., MOULDS, C., and FROEHLER, B. (1993). Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260, 1510-1513.

WALDER, R., and WALDER, J. (1988). Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 85,5011-5015.

WELLER, D., DALY, D., OLSON, W., and SUMMERTON, J. (1991). Molecular modeling of acyclic polyanide oligonucleotide analogues. J. Org. Chem. **56**, 6000-6006.

ZAMECNIK, P., and STEPHENSON, M. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75,280-284.

Address reprint requests to:
James Summerton, Ph.D.
ANTIVIRALS Inc.
4575 S.W. Research Way, Suite 200
Corvallis, OR 97333